E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).
Anjali S. Advani,Daniel J. DeAngelo,David I. Marks,Matthias Stelljes,Michaela Liedtke,Wendy Stock,Nicola Gökbuget,Susan O'Brien,Elias Jabbour,Akil Merchant,Tao Wang,Erik Vandendries,Alexander Neuhof,Hagop M. Kantarjian +13 more
TL;DR: O is a calicheamicin-conjugated antibody targeting CD22 on ALL blast cells and its use in R/R ALL patients or standard of care chemotherapy (SC) is recommended.
Journal ArticleDOI
Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML).
Rita Assi,Ana Alfonso Pierola,Devendra Kc,Yasmin Abaza,Abdallah Abou Zahr,Kamal Chamoun,Guillermo Montalban-Bravo,Koichi Takahashi,Elias Jabbour,Tapan M. Kadia,Farhad Ravandi,Jorge E. Cortes,Courtney D. DiNardo,Naval Daver,Gautam Borthakur,Naveen Pemmaraju,Marina Konopleva,Andrew Futreal,Hagop M. Kantarjian,Guillermo Garcia-Manero +19 more
TL;DR: A large number of AML patients with available NGS-based detection of somatic mutations had a median of 2 actionable mutations (AMs) and started new therapy after NGS results availability, suggesting broader use of testing will impact treatment and outcomes.
Journal ArticleDOI
Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
Lina Han,Qi Zhang,Ce Shi,Ce Shi,Joel D. Leverson,Monique Dail,Darren C. Phillips,Jun Chen,Sha S. Jin,Rodrigo Jacamo,Naval Daver,Elias Jabbour,Hagop M. Kantarjian,Michael Andreeff,Deepak Sampath,Marina Konopleva +15 more
TL;DR: The anti-tumor effects of concomitant BCL-2 and MAPK blockade by venetoclax in combination with MEK1/2 inhibitor GDC-0973 (cobimetinib) are evaluated and signaling patterns and B CL-2 family protein expression in AML stem/progenitor cells are investigated.
Journal ArticleDOI
Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan (90YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies
Issa F. Khouri,Bill Erwin,Alison M. Gulbis,Francesco Turturro,S. Cheenu Kappadath,Dustin A. Gress,Rosamar Valverde,Elias Jabbour,Roland L. Bassett,Aaron Jessop +9 more
TL;DR: It is hypothesized that the addition of escalated 90YIT dose to the recently published bendamustine+fludarabine conditioning regimen would facilitate early cytoreduction in patients with relapsed lymphoma and promote improved long-term disease control by the allogeneic graft.
Journal ArticleDOI
Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).
Elias Jabbour,Hagop M. Kantarjian,A. Megan Cornelison,Tapan M. Kadia,Mary-Alma Welch,Lynne V. Abruzzo,Jan A. Burger,Alessandra Ferrajoli,Guillermo Garcia-Manero,Jorge E. Cortes +9 more
TL;DR: It is concluded that cytogenetic abnormalities occur in Ph-negative cells in a small fraction of pts treated with 2 nd TKIs and usually have no clinical significance, but in rare instances they could signal the emergence of a new malignant clone.